1. NCCU Academic Hub
  2. 學術產出
  3. 文學院
  4. 期刊論文
  5. Item

學術產出-期刊論文

文章檢視/開啟

書目匯出

Google ScholarTM

政大圖書館

引文資訊

TAIR相關學術產出

題名 EUMENOL—Merck’s Patent Emmenagogue and its Chinese Connections (1896–1961)
作者 陳致宏
Chen, Chih-hung;Lee, Jen-der
貢獻者 歷史系
關鍵詞 Eumenol; danggui; Merck; women’s medicine; China
日期 2023-09
上傳時間 5-三月-2024 15:39:24 (UTC+8)
摘要 This article examines the rise and fall of Eumenol, Merck's patent emmenagogue extracted from danggui (當歸), and its destined connections with China. Understood to affect the blood, danggui, one of the most prolifically used substance among Chinese materia medica, had been included in recipes for women aged from before menarche to after menopause since the twelfth century, but it was not until its production and advertisement by the German pharmaceutical company that the multi-functional material was placed on the international stage with a sharpened gendered image. For Merck customers around the world, Eumenol was a long-awaited, harmless emmenagogue made from an obscure Chinese material; for Chinese who had been using the root to treat a wide range of disorders, the branded drug was a scientific refinement of a time-honored medicine. The success of Eumenol gave advocates of Chinese medicine a concrete example with which to rejuvenate their medical traditions, but the later cessation of Chinese imports forced Merck to eventually stop marketing the emmenagogue. Within this intersection of medicinal exchanges, Eumenol emerged as an indispensable piece of the puzzle in terms of both the history of an ancient remedy and the modernization of Chinese medicine.
關聯 East Asian Science, Technology and Society, pp.1-23
資料類型 article
DOI https://doi.org/10.1080/18752160.2023.2251784
dc.contributor 歷史系
dc.creator (作者) 陳致宏
dc.creator (作者) Chen, Chih-hung;Lee, Jen-der
dc.date (日期) 2023-09
dc.date.accessioned 5-三月-2024 15:39:24 (UTC+8)-
dc.date.available 5-三月-2024 15:39:24 (UTC+8)-
dc.date.issued (上傳時間) 5-三月-2024 15:39:24 (UTC+8)-
dc.identifier.uri (URI) https://nccur.lib.nccu.edu.tw/handle/140.119/150345-
dc.description.abstract (摘要) This article examines the rise and fall of Eumenol, Merck's patent emmenagogue extracted from danggui (當歸), and its destined connections with China. Understood to affect the blood, danggui, one of the most prolifically used substance among Chinese materia medica, had been included in recipes for women aged from before menarche to after menopause since the twelfth century, but it was not until its production and advertisement by the German pharmaceutical company that the multi-functional material was placed on the international stage with a sharpened gendered image. For Merck customers around the world, Eumenol was a long-awaited, harmless emmenagogue made from an obscure Chinese material; for Chinese who had been using the root to treat a wide range of disorders, the branded drug was a scientific refinement of a time-honored medicine. The success of Eumenol gave advocates of Chinese medicine a concrete example with which to rejuvenate their medical traditions, but the later cessation of Chinese imports forced Merck to eventually stop marketing the emmenagogue. Within this intersection of medicinal exchanges, Eumenol emerged as an indispensable piece of the puzzle in terms of both the history of an ancient remedy and the modernization of Chinese medicine.
dc.format.extent 109 bytes-
dc.format.mimetype text/html-
dc.relation (關聯) East Asian Science, Technology and Society, pp.1-23
dc.subject (關鍵詞) Eumenol; danggui; Merck; women’s medicine; China
dc.title (題名) EUMENOL—Merck’s Patent Emmenagogue and its Chinese Connections (1896–1961)
dc.type (資料類型) article
dc.identifier.doi (DOI) 10.1080/18752160.2023.2251784
dc.doi.uri (DOI) https://doi.org/10.1080/18752160.2023.2251784